Botanix Pharmaceuticals' (ASX:BOT) shareholders rejected its remuneration report at its annual general meeting on Thursday, according to a same-day Australian bourse filing.
Over 73% of the votes cast at the meeting were against the remuneration report.
The company's shares rose nearly 2% in recent trading on Thursday.